Amura is a structure-based drug discovery business specialising in diseases such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain and malaria. Amura has a proprietary technology platform (AMcore™) that provides a turnkey solution for the discovery of small-molecule inhibitors against cysteine peptidases (e.g. cathepsin enzymes); which are commercially attractive therapeutic targets. Amura compounds possess highly desirable drug-like properties; thereby facilitating the rapid and innovative discovery of orally active pharmaceutical ingredients across several disease areas. Amura has assembled advanced pre-clinical packages for its programmes demonstrating efficacy in disease-related animal models as well as safety pharmacology profiling. Amura intends to license out the programmes. Amura’s research and development activities are based at the Babraham Research Campus, Cambridge, United Kingdom.
Amura has licensing opportunities for its core business based around the AMcore™ technology. Amura also has licensing opportunities for its anti-bacterials programme based on ß-lactamase inhibitors.